Here, we describe the development and preclinical characterisation of CVGBM, an mRNA-based immunotherapeutic candidate for HLA-A*02:01-positive patients with surgically resected O6-methylguanine-DNA methyltransferase (MGMT)-unmethylated GBM following standard of care treatment. The gene discussed is HLA-A; the disease is glioblastoma.